We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
(MM) | NASDAQ:SIAL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 139.97 | 0 | 01:00:00 |
By Natalia Drozdiak and Christopher Alessi
FRANKFURT-- Pfizer Inc. and Germany's Merck KGaA are teaming up to develop a new tumor treatment product, in a move that will boost the U.S. company's oncology business but reduce its full-year earnings per share.
Merck said Monday it would receive $850 million upfront to jointly develop and commercialize an anti-PD-L1 antibody with Pfizer and could receive a further $2 billion in regulatory and commercial milestone payments. Merck is already developing the drug as a treatment against various types of tumors.
"It is the largest deal in the pharmaceutical industry for a single asset in this stage of development," said Belén Garijo, chief executive of Merck's pharmaceutical division. The deal also "enables Merck to accelerate its entry into the U.S. oncology market," Ms. Garijo added.
The two companies will also work to push Pfizer's anti-PD-1 antibody--another tumor fighting agent--into phase 1 trials, while Merck will co-promote Pfizer's lung cancer drug XALKORI in the U.S. and other markets.
As a result of the transaction, Pfizer is downgrading its previous 2014 reported diluted earnings per share guidance to between $1.40 and $1.49, from between $1.50 and $1.59.
Both companies will jointly fund development and commercialization costs and will share all revenues from selling any anti-PD-L1 or anti-PD-1 products, Merck said.
Merck added that about 20 immuno-oncology clinical development programs are set to begin next year.
Growth in Merck's pharmaceutical division, Merck Serono, was held back in the third quarter, reported Nov. 13, because of a 69% decline in royalty, license and commission income connected with patent expirations for arthritis drugs Humira and Enbrel. Third-quarter pharmaceutical sales were driven largely by growth in emerging markets such as China and Brazil.
The company has moved over the past year to bolster its non-pharmaceutical divisions through the acquisitions of the U.K.'s AZ Electronics PLC and U.S.-based Sigma-Aldrich Corp., a supplier of laboratory testing materials.
Merck KGaA isn't affiliated with Merck & Co. of the U.S.
Write to Natalia Drozdiak at natalia.drozdiak@wsj.com and Christopher Alessi at christopher.alessi@wsj.com
Access Investor Kit for Merck KGaA
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=DE0006599905
Access Investor Kit for Merck KGaA
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US5893391004
Access Investor Kit for Merck & Co., Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US58933Y1055
Access Investor Kit for Pfizer Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US7170811035
Access Investor Kit for Sigma-Aldrich Corp.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US8265521018
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year (MM) Chart |
1 Month (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions